found Documents: 650

Announcements & Press Releases, Regulatory Notice | 27 Nov 2020

Notification of Dilution of Voting Rights

1 item

London: Friday, November 27, 2020: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) was notified that CK Hutchison Holdings Limited (“CK Hutchison”) shareholding[1] in Chi-Med remains unchanged, at 332,478,770 ordinary shares

View Announcement (PDF)

Announcements & Press Releases, Group | 17 Nov 2020

Chi-Med Announces US$100 Million Equity Investment by CPP Investments

1 item

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION Hong Kong, Shanghai, & Florham Park, NJ: Tuesday

View Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology | 5 Nov 2020

Chi-Med Highlights HMPL-689 Clinical Data to be Presented at the 62nd ASH Annual Meeting

1 item

Hong Kong, Shanghai, & Florham Park, NJ: Thursday, November 5, 2020: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) today announces that initial analysis of the first in human HMPL-689 Phase I dose escalation study will be pre

Download Press Release (PDF)

Announcements & Press Releases, Group | 30 Oct 2020

Chi-Med to Attend Upcoming Industry and Investor Virtual Conferences

1 item

Hong Kong, Shanghai, & Florham Park, NJ: Friday, October 30, 2020: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) today announces that Mr. Christian Hogg, Chief Executive Officer of Chi-Med, will present or participate in the

Download Press Release (PDF)

Announcements & Press Releases, Regulatory Notice | 30 Oct 2020

Total Voting Rights

1 item

London: Friday, October 30, 2020: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) hereby notifies the market that as at October 30, 2020, the issued share capital of Chi-Med consisted of 711,025,545 ordinary shares of US$0.10 each,

View Announcement (PDF)

Announcements & Press Releases, Regulatory Notice | 30 Sep 2020

Total Voting Rights

1 item

London: Wednesday, September 30, 2020: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) hereby notifies the market that as at September 30, 2020, the issued share capital of Chi-Med consisted of 710,785,545 ordinary shares of US$0.1

View Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology, Press Releases | 20 Sep 2020

Chi-Med Highlights Surufatinib Phase III Results in Neuroendocrine Tumors at ESMO 2020 and Publications in The Lancet Oncology

1 item

― Phase III SANET-p demonstrated surufatinib reduces the risk of disease progression or death by 51% in patients with pancreatic neuroendocrine tumors (“NET”) ― ― SANET-p results complement previously presented positive Pha

Download Press Release (PDF)

Announcements & Press Releases, Oncology / Immunology, Press Releases | 17 Sep 2020

Chi-Med Announces Second NDA Acceptance in China for Surufatinib in Pancreatic Neuroendocrine Tumors

1 item

Hong Kong, Shanghai, & Florham Park, NJ: Thursday, September 17, 2020: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) today announces that its New Drug Application (“NDA”) for surufatinib for the treatment of patients with

Download Press Release (PDF)

Announcements & Press Releases, Oncology / Immunology, Press Releases | 4 Sep 2020

Chi-Med Initiates FRESCO-2, a Global Phase III Trial of Fruquintinib in Metastatic Colorectal Cancer

1 item

Hong Kong, Shanghai, & Florham Park, NJ: Friday, September 4, 2020: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) has initiated FRESCO-2, a Phase III registration study of fruquintinib for the treatment of patients with metas

Download Press Release (PDF)

Announcements & Press Releases, Oncology / Immunology, Press Releases | 3 Sep 2020

Chi-Med Initiates a Phase II Trial of HMPL-453 in Patients with Advanced Intrahepatic Cholangiocarcinoma in China

1 item

Hong Kong, Shanghai, & Florham Park, NJ: Thursday, September 3, 2020: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) has initiated a Phase II study of HMPL-453, its novel small molecule inhibitor targeting fibroblast growth fa

Download Press Release (PDF)

Announcements & Press Releases, Regulatory Notice | 28 Aug 2020

Total Voting Rights

1 item

London: Friday, August 28, 2020: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) hereby notifies the market that as at August 28, 2020, the issued share capital of Chi-Med consisted of 710,594,765 ordinary shares of US$0.10 each, w

View Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology, Press Releases | 24 Aug 2020

Chi-Med Highlights Clinical Data to be Presented at the Upcoming ESMO Virtual Congress 2020

1 item

Hong Kong, Shanghai, & Florham Park, NJ: Monday, August 24, 2020: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) today announces that new and updated analyses on the studies of surufatinib and fruquintinib will be presented

Download Press Release (PDF)

Announcements & Press Releases, Regulatory Notice | 12 Aug 2020

Grant of Share Options under Share Option Scheme

1 item

Hong Kong, Shanghai, & Florham Park, NJ: Wednesday, August 12, 2020: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) announces that on August 11, 2020, it granted share options under the Share Option Scheme conditionally adopte

View Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology, Press Releases | 10 Aug 2020

Chi-Med Plans to Submit Marketing Authorization Application for Surufatinib Following Scientific Advice from EMA’s CHMP

1 item

Hong Kong, Shanghai, & Florham Park, NJ: Monday, August 10, 2020: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) today announces that it received scientific advice from the European Medicines Agency's (“EMA”) Committee for

Download Press Release (PDF)

Announcements & Press Releases, Group | 30 Jul 2020

Chi-Med Reports 2020 Interim Results and Provides Updates on Key Clinical Programs

1 item

– Strong global pipeline progress – three U.S. FDA1 Fast Track Designations; surufatinib U.S. NDA2 preparations underway; and initiation of global Phase III for fruquintinib – – Two further NDAs submitted in China – savolitinib in

View Announcement (PDF)

Announcements & Press Releases, Regulatory Notice | 30 Jul 2020

Block Admission Application

1 item

London: Thursday, July 30, 2020: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) today announces an application has been made to the London Stock Exchange plc for a block admission of 30,221,458 ordinary shares, par value of US$0.1

Download Press Release (PDF)

Announcements & Press Releases, Oncology / Immunology, Press Releases | 28 Jul 2020

Chi-Med and Lilly to Collaborate in Commercializing Elunate® in China

1 item

Hong Kong, Shanghai, & Florham Park, NJ: Tuesday, July 28, 2020: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) and Eli Lilly and Company (“Lilly”) today announce an amendment to the 2013 License and Collaboration Agreeme

Download Press Release (PDF)

Announcements & Press Releases, Oncology / Immunology, Press Releases | 28 Jul 2020

Chi-Med’s NDA for Savolitinib in Non-Small Cell Lung Cancer Granted Priority Review in China

1 item

Hong Kong, Shanghai & Florham Park, NJ: Tuesday, July 28, 2020: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) today announced that the China National Medical Products Administration (“NMPA”) has granted Priority Review st

Download Press Release (PDF)

Announcements & Press Releases, Oncology / Immunology, Press Releases | 24 Jul 2020

Chi-Med Initiates a Phase I Trial of IDH1/2 Dual Inhibitor in Patients with Hematological Malignancies in China

1 item

— HMPL-306 is the ninth innovative oncology drug candidate discovered in house by Chi-Med — Hong Kong, Shanghai & Florham Park, NJ: Friday, July 24, 2020: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) has in

Download Press Release (PDF)

Announcements & Press Releases, Regulatory Notice | 8 Jul 2020

TR-1: Standard form for notification of major holdings

1 item

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: Hutch

View Announcement (PDF)

Announcements & Press Releases, Regulatory Notice | 7 Jul 2020

TR-1: Standard form for notification of major holdings

1 item

View Announcement (PDF)

Announcements & Press Releases, Regulatory Notice | 7 Jul 2020

Notification of Dilution of Voting Rights

1 item

London: Tuesday, July 7, 2020: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) was notified that CK Hutchison Holdings Limited (“CK Hutchison”) shareholding1 in Chi-Med remains unchanged, at 332,478,770 ordinary shares of par v

View Announcement (PDF)

Announcements & Press Releases, Regulatory Notice | 29 Jun 2020

Blocklisting Six Monthly Return

1 item

London: Monday, June 29, 2020: Hutchison China MediTech Limited (“Chi-Med” or the “Company”) (AIM/Nasdaq: HCM) announces the following blocklisting six monthly return: 1. Name of applicant: Hutchison China MediTech Limite

View Announcement (PDF)

Announcements & Press Releases, Group | 26 Jun 2020

Chi-Med to Announce 2020 Half-Year Financial Results

1 item

London: Friday, June 26, 2020: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) will be announcing its interim results for the six months ended June 30, 2020 on Thursday, July 30, 2020 at 12:00 noon British Summer Time (BST) (7:00 p

View Announcement (PDF)

Announcements & Press Releases, Group | 25 Jun 2020

Chi-Med Announces US$100 Million Equity Investment by General Atlantic

1 item

View Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology, Press Releases | 18 Jun 2020

Chi-Med Announces Fruquintinib Granted U.S. FDA Fast Track Designation for Metastatic Colorectal Cancer

1 item

London: Thursday, June 18, 2020: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) today announces that the U.S. Food and Drug Administration (“FDA”) has granted Fast Track Designation for the development of fruquintinib, for th

Download Press Release (PDF)

Announcements & Press Releases, Other Ventures, Press Releases | 9 Jun 2020

Chi-Med Announces US$95 million Guangzhou Land Compensation Agreement

1 item

London: Tuesday, June 9, 2020: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) today announces that Hutchison Whampoa Guangzhou Baiyunshan Chinese Medicine Company Limited (“HBYS”), its 50:50 joint venture with Guangzhou Baiyu

Download Press Release (PDF)

Announcements & Press Releases, Oncology / Immunology, Press Releases | 4 Jun 2020

Chi-Med Announces the Continuation of Phase III FRUTIGA Study of Fruquintinib in Second-Line Gastric Cancer in China Following a Planned Interim Data Review

1 item

London: Thursday, June 4, 2020: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) today announces that the Independent Data Monitoring Committee (IDMC) of the FRUTIGA study of fruquintinib has completed a planned interim data review.

Download Press Release (PDF)

Announcements & Press Releases, Oncology / Immunology, Press Releases | 1 Jun 2020

Chi-Med Plans to Submit NDA for Surufatinib Following Pre-NDA Meeting with the U.S. FDA

1 item

London: Monday June 1, 2020: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) today announces that it has held its pre-New Drug Application (“NDA”) meeting with the U.S. Food and Drug Administration (“FDA”) for surufatinib f

Download Press Release (PDF)

Announcements & Press Releases, Oncology / Immunology, Press Releases | 29 May 2020

Chi-Med Announces NDA Acceptance in China for Savolitinib in the Treatment of Non-Small Cell Lung Cancer with MET Exon 14 Skipping Mutations

1 item

Press Release — First NDA filing of savolitinib globally — — Chi-Med seeking first-in-class Chinese marketing authorization for a selective MET inhibitor — London: Friday, May 29, 2020: Hutchison China MediTech Limi

Download Press Release (PDF)

Announcements & Press Releases, Oncology / Immunology, Press Releases | 29 May 2020

Chi-Med to Discuss Select Global Clinical Trial Data Presented at ASCO20

1 item

Press Release ― Savolitinib in MET exon 14 skipping NSCLC efficacy evaluable patients demonstrated 49.2% ORR, 93.4% DCR and 9.6 months DoR, including 36% patients with more aggressive disease subtype ― ― Savolitinib vs. sunitinib stu

Download Press Release (PDF)

Announcements & Press Releases, Oncology / Immunology, Press Releases | 26 May 2020

Chi-Med and BeiGene Enter into Clinical Collaboration to Evaluate Combinations of Surufatinib and Fruquintinib with Tislelizumab

1 item

Press Release – Collaboration to explore multiple solid tumor cancer indications – – Initial development focused on multi-cohort trials in the U.S., Europe, China and Australia – LONDON, UK; CAMBRIDGE, Mass. and BEIJING

Download Press Release (PDF)

Announcements & Press Releases, Oncology / Immunology, Press Releases | 14 May 2020

Chi-Med Highlights Clinical Data to be Presented at the Upcoming ASCO20 Virtual Scientific Program

1 item

London: Thursday, May 14, 2020: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) today announces that new and updated analyses on the ongoing studies of savolitinib, surufatinib, and fruquintinib will be presented at the upcoming AS

Download Press Release (PDF)

Announcements & Press Releases, Group | 11 May 2020

Chi-Med to Attend Upcoming Investor Conferences

1 item

London: Monday, May 11, 2020: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) today announces that Mr Christian Hogg, Chief Executive Officer of Chi-Med, will participate in a virtual fireside chat at the Bank of America 2020 Healt

Download Press Release (PDF)

Announcements & Press Releases, Regulatory Notice | 29 Apr 2020

Grant of Share Options under Share Option Scheme

1 item

London: Wednesday, April 29, 2020: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) announces that on April 28, 2020, in accordance with its new incentive policy outlined in its full year results announcement on March 3, 2020, it gr

View Announcement (PDF)

Announcements & Press Releases, Regulatory Notice | 27 Apr 2020

Results of Annual General Meeting

1 item

London: Monday, April 27, 2020: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) today announces that all ordinary resolutions and special resolutions put to its Annual General Meeting (“AGM”) held on April 27, 2020 were duly pa

View Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology, Press Coverage | 22 Apr 2020

Chi-Med Highlights Presentations of Surufatinib at the Upcoming AACR Virtual Annual Meetings

1 item

London: Wednesday, April 22, 2020: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) today announces that new and updated analyses on the ongoing studies of surufatinib will be presented at the upcoming American Association for Cance

Download Press Release (PDF)

Announcements & Press Releases, Regulatory Notice | 21 Apr 2020

Grant of Awards under Long Term Incentive Plan and Share Options under Share Option Scheme

1 item

London: Tuesday, April 21, 2020: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) announces that on April 20, 2020, in accordance with the new incentive policy outlined in its full year results announcement on March 3, 2020, it

View Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology, Press Releases | 17 Apr 2020

Chi-Med Announces Surufatinib Granted U.S. FDA Fast Track Designations for the Treatment of Both Pancreatic and Non-Pancreatic Neuroendocrine Tumors

1 item

London: Friday, April 17, 2020: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) today announces that the U.S. Food and Drug Administration (“FDA”) has granted two Fast Track Designations for the development of surufatinib, for

Download Press Release (PDF)

Announcements & Press Releases, Oncology / Immunology, Press Releases | 31 Mar 2020

Chi-Med Initiates a Phase II Trial of HMPL-453 in Patients with Advanced Malignant Mesothelioma in China

1 item

London: Tuesday, March 31, 2020: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) has initiated a Phase II study of HMPL-453, its novel small molecule inhibitor targeting fibroblast growth factor receptors (“FGFR”), in patients

Download Press Release (PDF)

Announcements & Press Releases, Group | 25 Mar 2020

2019 Annual Report and Notice of Annual General Meeting

1 item

London: Wednesday, March 25, 2020: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/ AIM: HCM) today announces that its 2019 Annual Report together with the Notice of Annual General Meeting and the Form of Proxy (“AGM Materials”) have bee

View Announcement (PDF)

Announcements & Press Releases, Regulatory Notice | 9 Mar 2020

Vesting of awards under the Long Term Incentive Plan

1 item

London: Monday, March 9, 2020: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) announces that following the announcement of the 2019 annual results of Chi-Med on March 3, 2020, the following awards granted under the Long Term Incen

View Announcement (PDF)

Announcements & Press Releases, Group | 3 Mar 2020

Chi-Med Reports 2019 Full Year Results and Provides Updates on Key Clinical Programs

1 item

Company to Host Annual Results Conference Call Today at 1:00 p.m. GMT / 8:00 a.m. EST / 9:00 p.m. HKT London: Tuesday, March 3, 2020: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM), a commercial-stage biopharmaceutical comp

View Announcement (PDF)

Announcements & Press Releases, Group | 25 Feb 2020

Chi-Med to announce 2019 Final Results on Tuesday, March 3, 2020 – adjustment to announcement and presentation logistics due to travel restrictions

1 item

London: Tuesday, February 25, 2020: Further to its announcement dated January 31, 2020, Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) announced that its final results for the year ended December 31, 2019 will be released on Tuesd

View Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology, Press Releases | 10 Feb 2020

Chi-Med Highlights Updated Phase II Savolitinib / Imfinzi® Combination Data in Advanced Papillary Renal Cell Carcinoma at 2020 ASCO Genitourinary Cancers Symposium

1 item

Press Release London: Monday, February 10, 2020: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announced the availability of updated results from the Phase II CALYPSO study of the savolitinib / Imfinzi® (durvalumab) combi

Download Press Release (PDF)

Announcements & Press Releases, Group | 6 Feb 2020

Chi-Med Announces the Exercise of Underwriters’ Over-allotment Option for Public Offering of ADSs

1 item

View Announcement (PDF)

Announcements & Press Releases, Group | 31 Jan 2020

Chi-Med to Announce 2019 Final Results

1 item

The announcement has been updated on February 25, please see the updated announcement here. London: Friday, January 31, 2020: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) will announce its final results for the year ended Decem

View Announcement (PDF)

Announcements & Press Releases, Regulatory Notice | 29 Jan 2020